Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT immunogenicity and safety with or without Priorix-Tetra in toddlers
2006-006580-23Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine, GSK208136 and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease, measles, mumps and 2 more (4 arms), sponsored by GSK. Primary endpoints: rSBA-MenC titres, rSBA-MenA titres >=1:8 and 2 more. Started Mar 2007; status: completed.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccineGSK208136Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal diseasemeaslesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2006-006580-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006580-23.